Accelerating the Future of Health

COVID-19 responses from the health ecosystem

Responding to COVID-19 is an enormous challenge for companies of all sizes and in all sectors, not least life sciences. The pandemic is affecting the pharmaceutical ecosystem and highlighting the importance of health technology economically, politically, and socially.

Watch perspectives and insights of four thought leaders and entrepreneurs in the industry, as the industry reacts to COVID-19, shaping and accelerating the future of health.

Taking healthcare out of its clinical setting

Lucien Engelen is CEO at Transform.Health and Fellow at the Deloitte Center for the Edge. He presents the big picture and explains how healthcare is moving out of its traditional clinical setting into the wider community, adding to capacity and helping to reduce the burden on health systems. What do developments like telemedicine, virtual clinics and drive-thru testing mean for the future of health?

Bluetooth-based exposure alerting capabilities

Dana Lewis and Scott Leibrand are founders of CoEpi (Community Epidemiology in Action), an initiative around Bluetooth-based anonymous symptom sharing and exposure alerts. Part of the measures to reopen societies after the COVID-19 shutdown will be reliable tracking and tracing capabilities. They explain the use of the CoEpi open-source app for anonymous exposure alerting, based on voluntary sharing of symptoms and, in the future, confirmed COVID-19 test results, and they also consider the implications from privacy and security perspectives.

COVID-19 and vulnerable patient groups

Dana Lewis has direct experience with treatments for patients with high-risk medical conditions as a person with type 1 diabetes. She has designed an open source artificial pancreas to automate insulin dosing for Type 1 diabetes. In this video, she talks about what it means to be in a group who are considered to be more vulnerable to COVID-19.

Discover how Dana is making sense out of all the COVID-19 numbers she is seeing.

Steering medtech companies through difficult times

Carolina Aguilar is co-founder and CEO of INBRAIN Neuroelectronics. She explains how COVID-19 has put huge pressure on small medtech companies in dealing with concerns about employee wellbeing, staying in touch with customers and protecting supply chains. She also discusses how companies can continue to drive much-needed innovation when access to finance and liquidity is a challenge.

Deloitte Health Connect webcast recording

Our Deloitte Health Connect webcast brought together all four experts to discuss the acceleration of the future of health.

Click here to watch the full conversation.

Combating COVID-19 with resilience

Did you find this useful?